Nicholas James Ashton

Plasma and CSF neurofilament light chain measured by Simoa and Lumipulse: an inter-platform comparison across neurological disorders

Abstract Introduction Blood neurofilament light chain (NfL) is an accessible biomarker of neuroaxonal injury across a broad range of neurological disorders, but its clinical implementation requires robust cross-platform analytical and clinical comparability. The objective of this...

Plasma eMTBR-tau243 and p-tau205 as T2 biomarkers for biological staging and prognosis in Alzheimer’s disease

Abstract Plasma biomarkers that reflect distinct stages of Alzheimer’s disease (AD) could enable scalable biological staging. We evaluated phosphorylated tau (p-tau) species across multiple analytical platforms and the endogenously cleaved microtubule-binding region containing re...